Blueprint Medicines to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025
Blueprint Medicines (NASDAQ: BPMC) has scheduled its first quarter 2025 financial results announcement and corporate update for Thursday, May 1, 2025, at 8:00 a.m. ET. The company will host a live conference call and webcast for this presentation.
Participants can access the conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) with conference ID 082088. A webcast will be available in the Investors & Media section of Blueprint Medicines' website, remaining accessible for 30 days after the call.
Blueprint Medicines (NASDAQ: BPMC) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e un aggiornamento aziendale per giovedì 1 maggio 2025, alle 8:00 ET. La società terrà una conference call in diretta e una webcasting per questa presentazione.
I partecipanti potranno accedere alla conference call componendo il numero 833-470-1428 (nazionale) o 404-975-4839 (internazionale) con ID conferenza 082088. La webcasting sarà disponibile nella sezione Investitori e Media del sito web di Blueprint Medicines e resterà accessibile per 30 giorni dopo la chiamata.
Blueprint Medicines (NASDAQ: BPMC) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y una actualización corporativa para el jueves 1 de mayo de 2025, a las 8:00 a.m. ET. La empresa realizará una llamada en conferencia en vivo y una transmisión web para esta presentación.
Los participantes pueden acceder a la llamada marcando el 833-470-1428 (nacional) o 404-975-4839 (internacional) con el ID de conferencia 082088. La transmisión web estará disponible en la sección de Inversores y Medios del sitio web de Blueprint Medicines y permanecerá accesible durante 30 días después de la llamada.
Blueprint Medicines (NASDAQ: BPMC)는 2025년 1분기 재무 실적 발표 및 기업 업데이트를 2025년 5월 1일 목요일 오전 8시(동부시간)에 예정했습니다. 회사는 이 발표를 위해 라이브 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
참가자는 국내에서는 833-470-1428, 국제적으로는 404-975-4839 번호로 전화하여 회의 ID 082088을 입력해 컨퍼런스 콜에 참여할 수 있습니다. 웹캐스트는 Blueprint Medicines 웹사이트의 투자자 및 미디어 섹션에서 제공되며, 통화 후 30일간 시청할 수 있습니다.
Blueprint Medicines (NASDAQ : BPMC) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 et une mise à jour d'entreprise pour le jeudi 1er mai 2025 à 8h00 ET. La société organisera une conférence téléphonique en direct et une webdiffusion pour cette présentation.
Les participants peuvent accéder à la conférence téléphonique en composant le 833-470-1428 (domestique) ou le 404-975-4839 (international) avec l'ID de conférence 082088. Une webdiffusion sera disponible dans la section Investisseurs & Médias du site web de Blueprint Medicines et restera accessible pendant 30 jours après l'appel.
Blueprint Medicines (NASDAQ: BPMC) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 und ein Unternehmensupdate für Donnerstag, den 1. Mai 2025, um 8:00 Uhr ET geplant. Das Unternehmen wird eine Live-Konferenzschaltung und einen Webcast für diese Präsentation veranstalten.
Teilnehmer können die Konferenzschaltung über die Nummer 833-470-1428 (national) oder 404-975-4839 (international) mit der Konferenz-ID 082088 erreichen. Ein Webcast wird im Bereich Investoren & Medien auf der Website von Blueprint Medicines verfügbar sein und 30 Tage nach dem Anruf zugänglich bleiben.
- None.
- None.
To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 082088. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2025-financial-results-on-thursday-may-1-2025-302437712.html
SOURCE Blueprint Medicines Corporation
FAQ
When will Blueprint Medicines (BPMC) report Q1 2025 earnings?
How can investors access Blueprint Medicines' (BPMC) Q1 2025 earnings call?
How long will Blueprint Medicines' (BPMC) Q1 2025 earnings webcast be available?
Where can I find Blueprint Medicines' (BPMC) Q1 2025 earnings webcast?
